Clinical research
Pfizer Reports Failure in Persistent Pulmonary Hypertension, Progress in Duchenne Muscular Dystrophy
Pfizer’s intravenous (IV) Revatio (sildenafil), when added to inhaled nitric oxide (iNO), failed to meet its primary efficacy endpoint in treating newborns with Persistent Pulmonary Hypertension (PPHN).
The month of July is a slow one for the U.S. Food and Drug Administration (FDA), at least in terms of scheduled approval dates. Here’s a look at the three PDUFA dates the agency has on its calendar for the month.
Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate central nervous system.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
The U.S. Food and Drug Administration (FDA) gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder (NMOSD) in adults that express a specific biomarker.
Following an operational review, ImmunoGen will prioritize continued development of mirvetuximab, as well as a select portfolio of three earlier-stage product candidates.
AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer.
Biotech and pharma companies from across the globe share pipeline and business updates.
The higher doses of type 2 diabetes drug Trulicity significantly reduced A1C and also showed superiority in weight reduction. Here’s everything you should know about the drug.
Aldeyra Therapeutics reported that its reproxalap failed to meet its primary or secondary endpoints in noninfectious anterior uveitis.
PRESS RELEASES